Table 1 In vitro anticancer activities (IC50, μM) against three human tumor cell lines and one human normal cell line.
From: Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors
compounds | R | IC50 ± SD (μM) | |||
|---|---|---|---|---|---|
MCF-7 | HeLa | A549 | Lung cells | ||
3c | 2-FPh | 4.13 ± 0.01 | 2.69 ± 0.10 | 0.55 ± 0.02 | 178.2 ± 2.02 |
3d | Ph | 9.87 ± 1.00 | 10.25 ± 0.28 | 2.17 ± 0.02 | 136.1 ± 3.15 |
3e | 2-OmePh | 2.57 ± 0.02 | 1.55 ± 0.006 | 1.97 ± 0.001 | 189.3 ± 1.78 |
3f | 4-NO2Ph | 2.09 ± 0.01 | 4.99 ± 0.07 | 0.08 ± 0.003 | 201.6 ± 4.05 |
3i | 4-OmePh | 2.98 ± 0.09 | 0.90 ± 0.07 | 2.22 ± 0.05 | 197.5 ± 1.74 |
3m | Py | 2.87 ± 0.004 | 5.11 ± 0.006 | 1.55 ± 0.004 | 165.8 ± 0.59 |
3p | 3,4-ClPh | 0.22 ± 0.001 | 0.08 ± 0.0002 | 0.05 ± 0.0003 | 189.2 ± 3.82 |
3r | 3-triFPh | 4.97 ± 0.01 | 4.02 ± 0.01 | 0.33 ± 0.07 | 149.5 ± 3.03 |
Erlotinib | — | 0.15 ± 0.03 | 0.11 ± 0.01 | 0.10 ± 0.0004 | 195.2 ± 1.27 |
